Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer.

Abstract

BACKGROUND/AIM:

The presence of ascites in ovarian cancer patients is considered a negative prognostic factor. The underlying mechanisms are not clearly understood.

MATERIALS AND METHODS:

The amount of ascites was evaluated, preferably, using diffusion-weighted MRI at primary diagnosis in a retrospective cohort of 214 women with ovarian cancer, in an ordinal manner (amount of ascites: none, limited, moderate, abundant). In a prospective cohort comprising 45 women with ovarian cancer, IL-10 (interleukin), VEGF (vascular endothelial growth factor), TGF-β (transforming growth factor) and CCL-2 [chemokine (C-C) motif ligand 2] were measured at diagnosis (and at interval debulking, when available).

RESULTS:

Gradually increasing amounts of ascites were correlated significantly, even after correction for FIGO stage, with reduced survival (p<0.0001) and stronger immunosuppression (IL10 and VEGF). Neoadjuvant chemotherapy reduced immunosuppression, which was observed as a reduction in CCL-2, IL-10 and VEGF.

CONCLUSION:

The amount of ascites is an independent predictor of survival and correlates with increased immunosuppression.

• Authors: A N Coosemans, Thais Baert, Victoria D'Heygere, Roxanne Wouters, Lara DE Laet, Anais VAN Hoylandt, Gitte Thirion, Jolien Ceusters, Annouschka Laenen, Vincent Vandecaveye, Ignace Vergote
• Journal: Anticancer research (Anticancer Res) Vol. 39 Issue 11 Pg. 5953-5962 (Nov 2019) ISSN: 1791-7530 [Electronic] Greece
• PMID: 31704820 (Publication Type: Journal Article)
• Copyright: Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Topics

• Adenocarcinoma, Clear Cell (drug therapy, immunology, mortality, pathology)
• Adenocarcinoma, Mucinous (drug therapy, immunology, mortality, pathology)
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects)
• Ascites (etiology, mortality, pathology)
• Cystadenocarcinoma, Serous (drug therapy, immunology, mortality, pathology)
• Endometrial Neoplasms (drug therapy, immunology, mortality, pathology)
• Female
• Follow-Up Studies
• Humans
• Immunosuppression Therapy (mortality)
• Middle Aged
• Neoadjuvant Therapy (adverse effects)
• Neoplasm Invasiveness
• Ovarian Neoplasms (drug therapy, immunology, mortality, pathology)
• Prognosis
• Prospective Studies
• Retrospective Studies
• Survival Rate
• Young Adult